Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
スポンサーリンク
概要
- 論文の詳細を見る
http://creativecommons.org/licenses/by-nc-nd/3.0/Cholangiocarcinoma is an intractable cancer, with no effective therapy other than surgical resection. Elevated vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expressions are associated with the progression of cholangiocarcinoma. We therefore examined whether inhibition of VEGFR and EGFR could be a potential therapeutic target for cholangiocarcinoma. Vandetanib (ZD6474, ZACTIMA), a VEGFR-2/EGFR inhibitor, was evaluated. Four human cholangiocarcinoma cell lines were molecularly characterised and investigated for their response to vandetanib. In vitro, two cell lines (OZ and HuCCT1), both of which harboured KRAS mutation, were refractory to vandetanib, one cell line (TGBC24TKB) was somewhat resistant, and another cell line (TKKK) was sensitive. The most sensitive cell line (TKKK) had EGFR amplification. Vandetanib significantly inhibited the growth of TKKK xenografts at doses >= 12.5 mg kg(-1) day(-1) (P<0.05), but higher doses (50 mg kg(-1) day(-1), P<0.05) of vandetanib were required to inhibit the growth of OZ xenografts. Vandetanib (25 mg kg(-1) day(-1)) also significantly (P = 0.006) prolonged the time to metastasis in an intravenous model of TKKK metastasis. Inhibiting both VEGFR and EGFR signalling appears a promising therapeutic approach for cholangiocarcinoma. The absence of KRAS mutation and the presence of EGFR amplification may be potential predictive molecular marker of sensitivity to EGFR-targeted therapy in cholangiocarcinoma.
論文 | ランダム
- 18)透析経過中に狭心発作を頻発したSBEの1例 : 日本循環器学会第63回東海地方会
- 希薄高分子溶液の伸張流に関する研究 : 第2報,細管入口前の流速測定と伸張測定の算定
- 希薄高分子溶液の伸張流に関する研究 : 第1報、オリフィスを通る流れに関する実験
- 希薄高分子溶液の伸張流に関する研究 : 第1報,オリフィスを通る流れに関する実験
- 93)妊娠に合併したPheochromocytomaの1例 : 日本循環器学会第62回東海・第47回北陸合同地方会